The North America Rapid Acting Insulin Market would witness market growth of 4.9% CAGR during the forecast period (2021-2027). The geriatric population across the world has witnessed a substantial increment over the last several years. With the increasing geriatric population, the number of diabetic patients is also rising. In addition to it, the growth of the global rapid insulin market would be supplemented by some of the factors like growing awareness among the individuals about right diabetic care and technological developments in delivery devices of insulin.
As per the Centers for Disease Control and Prevention (CDC), 84.1 million people in America have prediabetes, condition if not treated will result in type 2 diabetes within the span of 5 years. With the growing number of diabetic patients across the world, the demand for rapid acting insulin is set to increase in order to regulate blood glucose levels. Without insulin, the patients are expected to suffer from blurred vision, weight loss, and intolerable thirst. Ultimately, unregulated diabetes can result in blindness, kidney failure, loss of limbs, gangrene, and eventually death. Therefore, these severe medical conditions necessitate the adoption of insulin as an effective method to treat diabetes and its consequent symptoms. Therefore, the market would witness bright growth prospects due to these reasons.
The onset of the COVID-19 pandemic is from the Wuhan City of China and it is now spread across the globe. Almost every country is grappling with the acute suffering of the pandemic. In addition, due to the lockdown restrictions imposed by numerous governments around the world, the majority of the markets have witnessed a sharp decline in their growth rate. Though, the global COVID-19 pandemic would bring growth possibilities for industries in which the management and treatment of chronic diseases are performed. As per the article by the American Diabetes Association in 2020, individuals suffering from diabetes are more prone to develop severe complications from the coronavirus.
The US market dominated the North America Insulin Aspart Market by Country in 2020, thereby, achieving a market value of $1,003.9 Million by 2027. The Canada market is experiencing a CAGR of 6.6% during (2021 - 2027). Additionally, The Mexico market would witness a CAGR of 6.3% during (2021 - 2027).
Based on Product Type, the market is segmented into Insulin Lispro, Insulin Aspart and Insulin Glulisine. Based on Indication, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Rapid Acting Insulin Market is Estimated to Reach USD 11.4 Billion by 2027 at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Adocia SA, Biocon Limited, Gan & Lee Pharmaceuticals, Geropharm LLC, Wockhardt Ltd., and MannKind Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Product Type
- Insulin Lispro
- Insulin Aspart
- Insulin Glulisine
By Indication
- Type 2 Diabetes
- Type 1 Diabetes
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Providers
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Merck & Co., Inc.
- Sanofi S.A.
- Novo Nordisk A/S
- Eli Lilly and Company
- Adocia SA
- Biocon Limited
- Gan & Lee Pharmaceuticals
- Geropharm LLC
- Wockhardt Ltd.
- MannKind Corporation
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Rapid Acting Insulin Market, by Product Type
1.4.2 North America Rapid Acting Insulin Market, by Indication
1.4.3 North America Rapid Acting Insulin Market, by Distribution Channel
1.4.4 North America Rapid Acting Insulin Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
Chapter 4. North America Rapid Acting Insulin Market by Product Type
4.1 North America Insulin Lispro Market by Country
4.2 North America Insulin Aspart Market by Country
4.3 North America Insulin Glulisine Market by Country
Chapter 5. North America Rapid Acting Insulin Market by Indication
5.1 North America Type 2 Diabetes Market by Country
5.2 North America Type 1 Diabetes Market by Country
Chapter 6. North America Rapid Acting Insulin Market by Distribution Channel
6.1 North America Hospital Pharmacies Market by Country
6.2 North America Drug Stores & Retail Pharmacies Market by Country
6.3 North America Online Providers Market by Country
Chapter 7. North America Rapid Acting Insulin Market by Country
7.1 US Rapid Acting Insulin Market
7.1.1 US Rapid Acting Insulin Market by Product Type
7.1.2 US Rapid Acting Insulin Market by Indication
7.1.3 US Rapid Acting Insulin Market by Distribution Channel
7.2 Canada Rapid Acting Insulin Market
7.2.1 Canada Rapid Acting Insulin Market by Product Type
7.2.2 Canada Rapid Acting Insulin Market by Indication
7.2.3 Canada Rapid Acting Insulin Market by Distribution Channel
7.3 Mexico Rapid Acting Insulin Market
7.3.1 Mexico Rapid Acting Insulin Market by Product Type
7.3.2 Mexico Rapid Acting Insulin Market by Indication
7.3.3 Mexico Rapid Acting Insulin Market by Distribution Channel
7.4 Rest of North America Rapid Acting Insulin Market
7.4.1 Rest of North America Rapid Acting Insulin Market by Product Type
7.5 Rest of North America Rapid Acting Insulin Market by Indication
7.5.1 Rest of North America Rapid Acting Insulin Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Merck & Co., Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.2 Sanofi S.A.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Product Launches and Product Expansions:
8.2.5.2 Approvals and Trials:
8.3 Novo Nordisk A/S
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental & Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Product Launches and Product Expansions:
8.3.5.2 Approvals and Trials:
8.3.5.3 Partnerships, Collaborations, and Agreements:
8.4 Eli Lilly and Company
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.4.5.2 Approvals and Trials:
8.4.5.3 Partnerships, Collaborations, and Agreements:
8.5 Adocia SA
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expense
8.5.4 Recent strategies and developments:
8.5.4.1 Approvals and Trials:
8.6 Biocon Limited
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Approvals and Trials:
8.7 Gan & Lee Pharmaceuticals
8.7.1 Company Overview
8.7.2 Financial Analysis
8.8 Geropharm LLC
8.8.1 Company Overview
8.9 Wockhardt Ltd.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. MannKind Corporation
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expense
8.10.4 Recent strategies and developments:
8.10.4.1 Acquisition and Mergers:
8.10.4.2 Partnerships, Collaborations, and Agreements:
TABLE 1 North America Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 2 North America Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Rapid Acting Insulin Market]
TABLE 4 Product Launches And Product Expansions– Rapid Acting Insulin Market
TABLE 5 Acquisition and Mergers– Rapid Acting Insulin Market
TABLE 6 Approvals and Trials– Rapid Acting Insulin Market
TABLE 7 North America Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 8 North America Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 9 North America Insulin Lispro Market by Country, 2017 - 2020, USD Million
TABLE 10 North America Insulin Lispro Market by Country, 2021 - 2027, USD Million
TABLE 11 North America Insulin Aspart Market by Country, 2017 - 2020, USD Million
TABLE 12 North America Insulin Aspart Market by Country, 2021 - 2027, USD Million
TABLE 13 North America Insulin Glulisine Market by Country, 2017 - 2020, USD Million
TABLE 14 North America Insulin Glulisine Market by Country, 2021 - 2027, USD Million
TABLE 15 North America Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 16 North America Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 17 North America Type 2 Diabetes Market by Country, 2017 - 2020, USD Million
TABLE 18 North America Type 2 Diabetes Market by Country, 2021 - 2027, USD Million
TABLE 19 North America Type 1 Diabetes Market by Country, 2017 - 2020, USD Million
TABLE 20 North America Type 1 Diabetes Market by Country, 2021 - 2027, USD Million
TABLE 21 North America Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 22 North America Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 23 North America Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 24 North America Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 25 North America Drug Stores & Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 26 North America Drug Stores & Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 27 North America Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 28 North America Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 29 North America Rapid Acting Insulin Market by Country, 2017 - 2020, USD Million
TABLE 30 North America Rapid Acting Insulin Market by Country, 2021 - 2027, USD Million
TABLE 31 US Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 32 US Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 33 US Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 34 US Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 35 US Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 36 US Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 37 US Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 38 US Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 39 Canada Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 40 Canada Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 41 Canada Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 42 Canada Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 43 Canada Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 44 Canada Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 45 Canada Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 46 Canada Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 47 Mexico Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 48 Mexico Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 49 Mexico Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 50 Mexico Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 51 Mexico Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 52 Mexico Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 53 Mexico Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 54 Mexico Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 55 Rest of North America Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 56 Rest of North America Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 57 Rest of North America Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 58 Rest of North America Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 59 Rest of North America Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 60 Rest of North America Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 61 Rest of North America Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 62 Rest of North America Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 63 key information - Merck & Co., Inc.
TABLE 64 Key Information – Sanofi S.A.
TABLE 65 Key information – Novo Nordisk A/S
TABLE 66 Key Information – Eli Lilly and Company
TABLE 67 key information – Adocia SA
TABLE 68 Key Information – Biocon Limited
TABLE 69 Key Information – Gan & Lee Pharmaceuticals
TABLE 70 key Information – Geropharm LLC
TABLE 71 Key Information – Wockhardt Ltd.
TABLE 72 Key Information – MannKind Corporation
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2016-2020)
FIG 4 Recent strategies and developments: Novo Nordisk A/S
FIG 5 Recent strategies and developments: Eli Lilly and Company
FIG 6 Recent strategies and developments: MannKind Corporation